Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Targeting connexin 43 with α–connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1

Figure 1

Connexin 43 activity and expression after ACT1 treatment in MCF7 cells. MCF7 cells were treated with vehicle, R-pep (200 μM), or ACT1 (200 μM) and assessed for (A) gap-FRAP. ANOVA with Bonferroni post-hoc analyses were used to determine statistical significance * = p < 0.05 vs Vehicle, τ = p < 0.05 vs R-Pep; ± SEM; n = 3 (B) Immunofluoresence staining and imaging of Cx43 (green) in MCF7 cells treated with R-pep or ACT1. Wheat germ agglutinin (WGA) in red was used to stain cell membranes.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us